Haisco Pharmaceutical Group company profile
Company profile
Haisco Pharmaceutical Group has 5,597 employees and is headquartered in Shannan, China.
China is the main market for Haisco Pharmaceutical Group Co., Ltd., which researches, develops, manufactures and sells pharmaceutical products there. Its portfolio covers anesthesia and analgesic drugs, endocrine system treatments, enteral and parenteral nutrition products, cardiovascular, psychiatric, tumor-related and digestive liver disease medicines, and treatments for other diseases. The group also works with Eli Lilly on medicines spanning several therapeutic fields, and it changed its name from Xizang Haisco Pharmaceutical Group in March 2016.
In the fiscal year ended December 2025, the company reported revenue of CNY 4.4 billion, up 17.9% from the previous year, and net profit of CNY 259.6 million. It employs 5,597 people and is headquartered in Shannan, China, where it was founded in 2000.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Headquarters
- No. 17 Sanxiang Avenue, 856000, Shannan
- Employees
- 5,597
- Chief executive
- Pangke Yan
- Founded
- 2000
- Fiscal year
- January - December
- Listing
- 002653 · SZSE
- Currency
- CNY
- ISIN
- CNE100001BC7
- Website
- haisco.com
Haisco Pharmaceutical Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Haisco Pharmaceutical Group002653 | China | $8.97B | 5,597 | 21.1% | 44.1 |
| ALTEOGEN196170 | South Korea | $9.05B | 181 | 47.2% | 97.1 |
| Genscript Biotech1548 | Hong Kong SAR China | $8.77B | 6,135 | 14.9% | — |
| Pharmaron Beijing300759 | China | $10.59B | 25,088 | 14.0% | 39.3 |
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $11.65B | 22,838 | 28.2% | 34.2 |
| Akeso9926 | Hong Kong SAR China | $6.81B | 4,082 | -30.7% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
